Given we are still two weeks away from the start of the AASLD conference, I'm more inclined to think that some investors felt the "intrinsic value" of the company as a whole depreciate too much since the FDA hold and have been accumulating for a while. Just my 2 cents.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.